Citations

Clear

3030 citation(s) found for "Susan, M".

Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors
Upadhyay, Rituraj , Grosshans, David R. , McGovern, Susan L. , McAleer, Mary Frances , Zaky, Wafik , Chintagumpala, Murali , Mahajan, Anita , Yeboa, D.N. , Paulino, Arnold C. , Paulino, Arnold C , Liao, Kai-Ping Eric

Mayo Clinic

Neuro-Oncology | February 11, 2022 | Volume: 24 | Issue: 9 | Pages: 1571-1581

10.1093/neuonc/noac044 | PMID 35157767 Get It

Abstract Background Brainstem toxicity after radiation therapy (RT) is a devastating complication and a particular concern with proton radiation (PBT). We investigated the incidence and clinical correlates of brainstem injury in pediatric brain tumors treated with PBT. Methods All patients <21 years with brain tumors treated with PBT at our institution from 2007–2019, with a brainstem Dmean >30 Gy and/or Dmax >50.4 Gy were included. Symptomatic brainstem injury (SBI) was defined as any new or progressive cranial neuropathy, ataxia, and/or motor weakness with corresponding radiographic abnormality within brainstem. Results A total of 595 patients were reviewed and 468 (medulloblastoma = 200, gliomas = 114, ependymoma = 87, ATRT = 43) met our inclusion criteria. Median age at RT was 6.3 years and median prescribed RT dose was 54Gy [RBE]. Fifteen patients (3.2%) developed SBI, at a median of 4 months after RT. Grades 2, 3, 4, and 5 brainstem injuries were seen in 7, 5, 1, and 2 patients respectively. Asymptomatic radiographic changes were seen in 51 patients (10.9%). SBI was significantly higher in patients with age ≤3 years, female gender, ATRT histology, patients receiving high-dose chemotherapy with stem cell rescue, and those not receiving craniospinal irradiation. Patients with SBI had a significantly higher V50–52. In 2014, our institution started using strict brainstem dose constraints (Dmax ≤57 Gy, Dmean ≤52.4 Gy, and V54≤10%). There was a trend towards decrease in SBI from 4.4% (2007-2013) to 1.5% (2014–2019) (P = .089) without affecting survival. Conclusion Our results suggest a low risk of SBI after PBT for pediatric brain tumors, comparable to photon therapy. A lower risk was seen after adopting strict brainstem dose constraints.
Behavioral parenting skills as a novel target for improving medication adherence in young children: Feasibility and acceptability of the CareMeds intervention
Bouchard, Elizabeth , Patel, Hital, Vincent, Paula C., LaValley, Susan, Devonish, Julia A. , Wadium, Jessica, Kelly, Kara M. , Epstein, Leonard H. , Wen, Xiaozhong

Mayo Clinic

Pediatric Hematology and Oncology | February 10, 2022 | Volume: 39 | Issue: 6 | Pages: 529-539

10.1080/08880018.2022.2025964 | PMID 35139726 Get It

Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States
Barreto, Jason N. , Krantz, Elizabeth M. , Nagel, Jerod , Dadwal, Sanjeet , Seo, Susan K. , Liu, Catherine , Liu, Catherine , Aitken, Samuel L

Mayo Clinic

Open Forum Infectious Diseases | February 8, 2022 | Volume: 9 | Issue: 3 | Pages: No page available

10.1093/ofid/ofac005 | PMID 35155714 Get It

Abstract Background Contemporary information regarding fever and neutropenia (FN) management, including approaches to antibacterial prophylaxis, empiric therapy, and de-escalation across US cancer centers, is lacking. Methods This was a self-administered, electronic, cross-sectional survey of antimicrobial stewardship physicians and pharmacists at US cancer centers. The survey ascertained institutional practices and individual attitudes on FN management in high-risk cancer patients. A 5-point Likert scale assessed individual attitudes. Results Providers from 31 of 86 hospitals (36%) responded, and FN management guidelines existed in most (29/31, 94%) hospitals. Antibacterial prophylaxis was recommended in 27/31 (87%) hospitals, with levofloxacin as the preferred agent (23/27, 85%). Cefepime was the most recommended agent for empiric FN treatment (26/29, 90%). Most institutional guidelines (26/29, 90%) recommended against routine addition of empiric gram-positive agents except for specific scenarios. Eighteen of 29 (62%) hospitals explicitly provided guidance on de-escalation of empiric, systemic antibacterial therapy; however, timing of de-escalation was variable according to clinical scenario. Among 34 individual respondents, a majority agreed with use of antibiotic prophylaxis in high-risk patients (25, 74%). Interestingly, only 10 (29%) respondents indicated agreement with the statement that benefits of antibiotic prophylaxis outweigh potential harms. Conclusion Most US cancer centers surveyed had institutional FN management guidelines. Antibiotic de-escalation guidance was lacking in nearly 40% of centers, with heterogeneity in approaches when recommendations existed. Further research is needed to inform FN guidelines on antibacterial prophylaxis and therapy de-escalation.
Comparative Effectiveness of Landmark-guided Greater Occipital Nerve (GON) Block at the Superior Nuchal Line Versus Ultrasound-guided GON Block at the Level of C2
Kissoon, Narayan R., O’Brien, Travis G., Bendel, Markus A., Eldrige, Jason S., Hagedorn, Jonathan M., Mauck, William D., Moeschler, Susan M., Olatoye, Oludare O., Pittelkow, Thomas P., Watson, James C., Pingree, Matthew J., Kissoon, Narayan R., O’Brien, Travis G., Bendel, Markus A., Eldrige, Jason S., Hagedorn, Jonathan M., Mauck, William D., Moeschler, Susan M., Olatoye, Oludare O., Pittelkow, Thomas P., Watson, James C., Pingree, Matthew J.

Mayo Clinic

The Clinical Journal of Pain | February 8, 2022 | Volume: 38 | Issue: 4 | Pages: 271-278

10.1097/ajp.0000000000001023 | PMID 35132029 Get It

Objectives: The purpose of this single center, prospective randomized controlled trial was to compare clinical outcomes between an ultrasound-guided greater occipital nerve block (GONB) at the C2 vertebral level versus landmark-based GONB at the superior nuchal line. Methods: Patients with occipital neuralgia or cervicogenic headache were randomized to receive either a landmark-based GONB with sham ultrasound at the superior nuchal line or ultrasound-guided GONB at the C2 vertebral level with blinding of patients and data analysis investigators. Clinical outcomes were assessed at 30 minutes, 2 weeks, and 4 weeks postinjection. Results: Thirty-two patients were recruited with 16 participants in each group. Despite randomization, the ultrasound-guided GONB group reported higher numeric rating scale (NRS) scores at baseline. Those in the ultrasound-guided GONB group had a significant decrease in NRS from baseline compared with the landmark-based GONB group at 30 minutes (change of NRS of 4.0 vs. 2.0) and 4-week time points (change of NRS of 2.5 vs. −0.5). Both groups were found to have significant decreases in Headache Impact Test-6. The ultrasound-guided GONB had significant improvements in NRS, severe headache days, and analgesic use at 4 weeks when compared with baseline. No serious adverse events occurred in either group. Conclusions: Ultrasound-guided GONBs may provide superior pain reduction at 4 weeks when compared with landmark-based GONBs for patients with occipital neuralgia or cervicogenic headache.
Multi‐institutional review of non‐hypospadiac penile urethral stricture management and outcomes
Abramowitz, David , Sam, Andre‐Philippe , Pachorek, Mark, Martins, Francisco E. , Angulo, J.C. , Simhan, Jay , Li, Eric , Policastro, Connor, Ramírez-Pérez, E. A. , Burks, Frank , Shetty, Zubin, Venkatesan, K. , Hunter, Craig, Gallegos, Maxx , Foreman, Jordan , Pariser, Joseph J. , MacDonald, Susan M. , Warner, Jonathan N. , Martins, Francisco , Warner, Jonathan, Ruel, Nora H. , Nikolavsky, Dmitriy , Kasabwala, Khushabu , Lopez, Damian

Mayo Clinic

International Journal of Urology | February 3, 2022 | Volume: 29 | Issue: 5 | Pages: 376-382

10.1111/iju.14786 | PMID 35118726 Get It

Objectives Penile urethral stricture disease not associated with hypospadias is rare, and there is a wide range of commonly used surgical repair techniques for this disease. We sought to compile a multi‐institutional database of patients who had surgical correction of strictures in the penile urethra not limited to the meatus, and who had no history of hypospadias, for analysis using the Trauma and Urologic Reconstructive Network of Surgeons length, urethral segment and etiology classification system. Methods A retrospective database from 13 institutions was compiled of patients who had undergone surgical correction of Trauma and Urologic Reconstructive Network of Surgeons length, urethral segment and etiology urethral stricture segments S2b/S2c and excluding E5, with a minimum follow‐up time of 4 months. Failure was defined as cystoscopically confirmed recurrence of a stricture measuring less than 16‐Fr. Results We analyzed 222 patients with a median age of 57 years and a follow‐up of 49 months. The overall surgical success rate was 80.2%. On multivariate analysis, the two variables identified that were predictive of surgical success were stricture length ≤2 cm as well as use of a buccal mucosa graft as compared to use of a fasciocutaneous flap, which had success rates of 83% and 52%, respectively ( P = 0.0004). No statistically significant differences were found based on incisional approach or surgical technique, nor were outcomes different based on etiology or preoperative patient demographics. Conclusions Surgical repair of penile urethral strictures of non‐hypospadiac origin have a favorable overall success rate, at 80.2%. Regardless of incisional approach or surgical technique, all operations appear to have similar outcomes other than repairs using fasciocutaneous flap, which were statistically less successful than those using buccal mucosa graft.
Research Goes Red: Early Experience With a Participant-Centric Registry
Gilchrist, Susan C. , Hall, Jennifer L. , Khandelwal, Abha , Hidalgo, Bertha , Kinzy, Claire, Mallya, Pratheek , Conners, Katie, Stevens, Laura , Alger, Heather M. , Wexler, Laura, Mega, Jessica L. , Mieres, Jennifer H. , Roger, Véronique L. , Stevens, Laura M , Alger, Heather M , Mehta, Laxmi , Hernandez, Adrian , Hayes, Sharonne N , Jessup, Mariell , Roger, Veronique L , Hall, Jennifer L , Aggarwal, Brooke , Mehta, Laxmi S. , Hernandez, Adrian F. , Hayes, Sharonne N.

Mayo Clinic

Circulation Research | February 3, 2022 | Volume: 130 | Issue: 3 | Pages: 343-351

10.1161/circresaha.121.320403 | PMID 35113661 Get It

Rationale: Cardiovascular disease remains the leading cause of death in women. To address its determinants including persisting cardiovascular risk factors amplified by sex and race inequities, novel personalized approaches are needed grounded in the engagement of participants in research and prevention. Objective: To report on a participant-centric and personalized dynamic registry designed to address persistent gaps in understanding and managing cardiovascular disease in women. Methods and Results: The American Heart Association and Verily launched the Research Goes Red registry (RGR) in 2019, as an online research platform available to consenting individuals over the age of 18 years in the United States. RGR aims to bring participants and researchers together to expand knowledge by collecting data and providing an open-source longitudinal dynamic registry for conducting research studies. As of July 2021, 15 350 individuals have engaged with RGR. Mean age of participants was 48.0 48.0±0.2 years with a majority identifying as female and either non-Hispanic White (75.7%) or Black (10.5%). In addition to 6 targeted health surveys, RGR has deployed 2 American Heart Association-sponsored prospective clinical studies based on participants’ areas of interest. The first study focuses on perimenopausal weight gain, developed in response to a health concerns survey. The second study is designed to test the use of social media campaigns to increase awareness and participation in cardiovascular disease research among underrepresented millennial women. Conclusions: RGR is a novel online participant-centric platform that has successfully engaged women and provided critical data on women’s heart health to guide research. Priorities for the growth of RGR are centered on increasing reach and diversity of participants, and engaging researchers to work within their communities to leverage the platform to address knowledge gaps and improve women’s health.
Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse
Roselli, Carolina , Yu, Mengyao , Nauffal, Victor , Georges, Adrien , Love, Katie , Weng, Lu‐Chen , Delling, Francesca N. , Maurya, Svetlana , Schrölkamp, Maren , Tfelt‐Hansen, Jacob , Jeunemaı̂tre, Xavier , Debette, Stéphanie , Guan, Wyliena , Body, Simon C. , Shah, Svati H. , Samad, Zainab , Kyryachenko, Sergiy , Haynes, Carol , Rienstra, Michiel , Hamer, Inez J. Wijdh‐den , Siland, Joylene E. , Levine, Robert A. , Benjamin, Emelia J. , Horne, Benjamin D. , Muhlestein, Joseph B. , Benfari, Giovanni , Natale, Andrea , Trivedi, Chintan , Shoemaker, Moore B., Yoneda, Zachary T. , Baker, Michael , Slaugenhaupt, Susan, Dina, Christian , Lubitz, Steven A. , Bouatia‐Naji, Nabila , Milan, David J. , Yang, Qiong , Love, Katie , Weng, Lu-Chen , Delling, Francesca N , Maurya, Svetlana R , Schrölkamp, Maren , Tfelt-Hansen, Jacob , Debette, Stephanie , Amouyel, Philippe , Guan, Wyliena , Muehlschlegel, Jochen D , Body, Simon C , Shah, Svati , Kyryachenko, Sergiy , Haynes, Carol , Rienstra, Michiel , Le Tourneau, Thierry , Wijdh-Den Hamer, Inez J , Siland, Joylene E , Jacques Schott, Jean , Levine, Robert A , Benjamin, Emelia J , Vasan, Ramachandran S , Horne, Benjamin D , Muhlestein, Joseph B , Benfari, Giovanni , Enriquez-Sarano, Maurice , Yoneda, Zachary T , Baker, Michael T , Farber-Eger, Eric H , Norris, Russell A , Dina, Christian , Lubitz, Steven A , Bouatia-Naji, Nabila , Ellinor, Patrick T , Natale, Andrea , Hagège, Albert Alain , Amouyel, Philippe , Tourneau, Thierry Le , Probst, Vincent , Roussel, Ronan , Knowlton, Kirk U. , Schott, Jean‐Jacques , Vasan, Ramachandran S. , Enriquez‐Sarano, Maurice , Mohanty, Sanghamitra , Wells, Quinn S. , Farber‐Eger, Eric , Michelena, Héctor I. , Lundby, Alicia , Ellinor, Patrick T.

Mayo Clinic

European Heart Journal | February 1, 2022 | Volume: 43 | Issue: 17 | Pages: 1668-1680

10.1093/eurheartj/ehac049 | PMID 35245370 Get It

Abstract Aims Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of >2% in the general adult population. Despite this high incidence, there is a limited understanding of the molecular mechanism of this disease, and no medical therapy is available for this disease. We aimed to elucidate the genetic basis of MVP in order to better understand this complex disorder. Methods and results We performed a meta-analysis of six genome-wide association studies that included 4884 cases and 434 649 controls. We identified 14 loci associated with MVP in our primary analysis and 2 additional loci associated with a subset of the samples that additionally underwent mitral valve surgery. Integration of epigenetic, transcriptional, and proteomic data identified candidate MVP genes including LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3. We created a polygenic risk score (PRS) for MVP and showed an improved MVP risk prediction beyond age, sex, and clinical risk factors. Conclusion We identified 14 genetic loci that are associated with MVP. Multiple analyses identified candidate genes including two transforming growth factor-β signalling molecules and spectrin β. We present the first PRS for MVP that could eventually aid risk stratification of patients for MVP screening in a clinical setting. These findings advance our understanding of this common valvular heart disease and may reveal novel therapeutic targets for intervention.
Cross‐sectional amyloid and tau PET in cognitively normal older adults enrolled in the U.S. POINTER lifestyle intervention trial
Borowski, Bret, Murphy, Alice, Ward, Tyler J. , Gordineer, Leslie, Woolard, Nancy , Jagust, William J. , Lovato, Laura, Masdeu, Joseph C. , Oh, Hwamee , Aggarwal, Neelum T. , Snyder, Heather M. , Whitmer, Rachel A. , Landau, Susan , Group, the U.S. POINTER Study, Harrison, Theresa M. , Vemuri, Prashanthi , Koeppe, Robert A. , Lockhart, Samuel N. , Jung, Youngkyoo , Espeland, Mark Andrew , Harvey, Danielle , Toga, Arthur W. , Masdeu, Joseph C , Gitelman, Darren R. , Carrillo, María C. , Baker, Laura D. , DeCarli, Charles , Group, the U.S. POINTER Study

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.055306 Get It

AbstractBackgroundThe U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a 2‐year randomized controlled trial to evaluate the effect of lifestyle interventions in older adults (60‐79 years) who are cognitively unimpaired but at increased risk for cognitive decline/dementia due to factors such as cardiovascular disease and family history. The POINTER Imaging ancillary study is collecting PET and MRI data to evaluate neuroimaging biomarkers of AD and cerebrovascular pathophysiology in this at‐risk sample.MethodPOINTER Imaging is actively enrolling 1250 participants, 23% from under‐represented racial/ethnic groups (URG), recruited from five U.S. POINTER clinical sites. Participants have undergone PET imaging with [18F]Florbetaben (FBB) to measure Aβ and [18F]MK‐6240 to measure tau burden, as well as MRI to measure brain morphometry, white matter hyperintensities and cerebral blood flow. FBB and MK‐6240 data were quality checked, pre‐processed, and quantified using previously validated methods. PET images were coregistered to a structural MRI, which was also used to create FreeSurfer‐defined reference regions and regions of interest. We examined PET imaging measures (global Aβ, regional tau) and basic demographic (age, sex, race/ethnicity) characteristics of the sample.Result96 participants (mean age 69.3±5.0) have been enrolled in POINTER Imaging. Of these, 59 (61%) are women and 22 (23%) are URG, which is similar to rates of women (75%) and URG (22%) in the main trial. This dataset is <10% of targeted enrollment, was predominantly recruited from 2/5 clinical sites and may not represent the final imaging cohort. FBB quantification (N=20) revealed a mean cortical summary SUVR of 1.09±0.12 (19.6±18.4 centiloids) (whole cerebellum normalization; previously validated positivity threshold=1.08), and 8/20 (40%) of these participants were Aβ+ (Fig. 1A). MK‐6240 quantification (N=23) showed predominantly no/minimal binding with a few exceptions in medial and lateral temporal lobes (Fig. 1B&C).ConclusionThe POINTER imaging study is meeting the target URG enrollment and representative of the main U.S. POINTER trial. Higher frequency of Aβ positivity than published in population cohorts coupled with greater cardiovascular risk factors among POINTER participants highlights our success in recruiting individuals at increased risk of cognitive decline.
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration
Banga, Yasmin B, Lai, Yujung, Kim, Priscilla , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Brushaber, Danielle , Bordelon, Yvette , Dickerson, Brad C., Dickinson, Susan, Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fishman, Ann, Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kornak, John , Lagone, Emma, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Manoochehri, Masood , Masdeu, Joseph C. , McGinnis, Scott, Mendez, Mario F, Miyagawa, Toji , Nelson, K. , Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Sabbagh, Marwan N. , Salmon, David P. , Savica, Rodolfo , Staffaroni, Adam M. , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Jack C. , Weıntraub, Sandra , Wheaton, Diana, Wong, Benjamin , Boeve, Bradley F. , Appleby, Brian S. , Biernacka, Joanna M. , Botha, Hugo , Bozoki, Andrea C , Brannelly, Patrick , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Gendron, Tania F. , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F, Miller, Bruce L. , Nelson, Kevin M, Pascual, Belén , Pottier, Cyril , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052495 Get It

AbstractBackgroundFrontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative conditions, affecting the frontal and/or temporal lobes. Ongoing research has provided insight into developing clinical trials for FTLD and key clinical measures such as structural MRI. To inform clinical trial design and optimize participation, it is imperative to explore facilitators and barriers for potential candidates.ObjectiveThe objective of this study is to explore facilitators and barriers to participating in future clinical trials for FTLD.MethodsAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) are observational studies focused on characterizing FTLD syndromes in preparation for clinical trials. The 584 participants enrolled across 18 research sites in the United States and Canada completed a survey assessing interest in clinical trial participation.Results29% of respondents self‐reported as patients (63±10 years), 26% self‐reported as caregivers answering on behalf of patients (65±10 years), and 45% self‐reported as healthy but at risk for FTLD (48±14 years). Travel reimbursement was the most common factor reported to positively influence participation (≧66%), with the healthy but at risk group showing the strongest endorsement (83%). Cost and time involved in travel were possible barriers for about half of the patients (48%) and healthy but at risk respondents (53%). The respondents value receiving feedback on the study findings (≧80%) and being informed of their individual disease progression (≧75%). Particularly, keeping participation confidential was very important for the healthy but at risk group (62%). In regard to research assessments, most participants demonstrated a high interest in physical and neurological exams at a research center (≧87%) whereas only half were interested in doing more invasive procedures such as the lumbar puncture (≧52%). Overall, respondents showed a positive attitude and support for research participation (≧77%) and trusted that their health information would remain confidential in a clinical trial (≧53%).ConclusionsFavorable attitudes and interest towards medical research exist among participants. To optimize participation, clinical trials should allocate funding for travel and involve participants in feedback about study results and their disease progression. Alternatives to invasive assessments may increase participation.